Population pharmacokinetic and pharmacodynamic modeling of Freefol-MCT® in healthy volunteers

Asan Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1. Adults older than 20 years old.
•2. Within 60 days from the trial, normal state from the tests of history taking, vital signs, 12-lead ECG, blood tests, urine test.
•3. Volunteers who agreed with the informed consents.

•1. Persons with cardiovascular, pulmonary, renal, endocrinal diseases, bleeding tendency, gastrointestinal disease, cerebral nervous system problems, psychological problems or history of meningitis.
•2. Within 4 weeks from the trial, persons who had acute orgal dysfunction or acute diseases.
•3. Within 2 months from the trial, persons who had significant hematological disease, or donated the whole blood.
•4. Persons with significant neuropsychological diseases.
•5. Drug abuse.
•6. History of hypersensitivity of drugs.
•7. HBV Ag(+), HCV Ag(+), VDRL(+), AIDS Ab(+).
•8. Within 2 months from the trial, history of taking of other medication from other clinical trial.
•9. History of smoking or drinking alcohol within 2 weeks from the trial.
•10. Taking of vitamines or minerals regularly.
•11. Pregnancy.
•12. Except for that, researchers made a decision.

发起方